Riccardo Valdez

University of Michigan

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Lihong Liu

Columbia University Vagelos College of Physicians and Surgeons

UNITED STATES

View details

Liyuan Liu

Columbia University Irving Medical Center

UNITED STATES

View details

Claudio Mosse

Chief

VA Tennessee Valley Healthcare System

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Riccardo Valdez

Research Interests

Explore related searches

Contact this professor

Articles (13)

KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2

Smooth Muscle Myosin Heavy Chain Expression in Nodal and Extranodal Follicular Dendritic Cell Sarcoma

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.

Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.

Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 2.2024

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.

Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.

Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.

SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster

Collaborators (3)

Lihong Liu

Liyuan Liu

Claudio Mosse

Make your next move.